Nano-anticancer promise in Phase II ovarian cancer trial
This article was originally published in Scrip
CRLX101, Cerulean Pharma's investigational 'nanopharmaceutical' has met its primary efficacy endpoint in an ongoing single-arm Phase II monotherapy trial in relapsed ovarian cancer.
You may also be interested in...
Cerulean will cut its staff by almost half to reprioritize its remaining cash as it recovers from a clinical trial failure for its lead drug candidate that shifts the program's immediate focus from kidney to ovarian cancer.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.